Clopidogrel for Proteinuria Reduction in Focal Segmental Glomerulosclerosis
Phase 2 Trial Design
Recent publication
The ClopiD4FSGS study is a phase II trial conducted by the Medical University of Vienna, sponsored by Delta 4 and supported by the Austrian Society of Nephrology. It is investigating the efficacy of clopidogrel in reducing proteinuria in patients with focal segmental glomerulosclerosis. Patients who may benefit from clopidogrel will be selected from the ARREST NEPHROSIS registry. Several centres are involved in the study and the registry, including the University Hospital St. Pölten with Clin. Ass. Prof. Dr Martin Wiesholzer, Head of the Clinical Division of Internal Medicine 1. The study design has been published in the open access journal Kidney International Reports.
Daniel-Fischer, L, Antlanger, M, Cejka, D, Eller, K, Gauckler, P, Odler, B, Rudnicki, M, Säemann, MD, Schmidt, A, Sunder-Plassmann, G, Wiesholzer, M, Windpessl, M, Zitt, E, Koenig, F, Greenbaum, LA, Kronbichler, A & Aufricht, C 2024, 'Clopidogrel for Proteinuria Reduction in Focal Segmental Glomerulosclerosis: Phase 2 Trial Design', Kidney International Reports, vol. 9, no. 2, pp. 478-481. https://doi.org/10.1016/j.ekir.2023.10.027
Prim. Clin. Ass. Prof. Dr. Martin Friedrich Wiesholzer
Division of Internal Medicine 1 (University Hospital St. Pölten)
